Asian trends in primary androgen depletion therapy on prostate cancer

Cancer Biology and Medicine

Volumn 10, Issue 4, 2013, Pages 187-191

  Akaza, Hideyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Androgen depletion therapy; Asia; Prostate cancer

Indexed keywords

ANDROGEN DEPLETION THERAPY; ANDROGEN THERAPY; ASIA; ASIAN; CANCER LOCALIZATION; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; JAPAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROSTATE CANCER; REGISTER; REVIEW; TREND STUDY; TUMOR INVASION; UNITED STATES;

EID: 84891315944     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2013.04.002     Document Type: Review

References (21)

1. Akaza H, Naito S, Cheng C, Kaisary A, Soebadi D M, Umbas R, et al. Asian trends in prostate cancer hormone therapy. Gan To Kagaku Ryoho 2002;29:1951-1961.
2. Akaza H, Chang S J, Chen K K, Esuvaranathan K, Fujioka T, Hirao Y, et al. The 2nd conference on Asian trends in prostate cancer hormone therapy. Gan To Kagaku Ryoho 2003;30:1533-1542.
3. Akaza H, Naito S, Chang S J, Chen K K, Cheng C, Choi H Y, et al. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy. Gan To Kagaku Ryoho 2004;31:1285-1295.
4. Akaza H, Moore M A, Chang S J, Cheng C, Choi H Y, Esuvaranathan K, et al. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy. Asian Pac J Cancer Prev 2007;8:3-12.
5. Cheng C, Akaza H, Chen K K, Moore M A, Naito S, Song J M, et al. Prostate cancer control-aims of the UICC Asia Regional Office Consortium. Asian Pac J Cancer Prev 2006;7:350-368.
6. Namiki M, Akaza H, Lee S E, Song J M, Umbas R, Zhou L, et al. Prostate Cancer Working Group report. Jpn J Clin Oncol 2010;40 Suppl 1:i70-75.
7. Available online: http://www.linkedin.com/pub/asian-pacificprostate-society/56/94a/352
8. Available online: http://demo.nccn.org/professionals/physician_gls/PDF/kidney-asia.pdf
9. Available online: http://demo.nccn.org/ professionals/physician_gls/PDF/prostate-asia.pdf
10. Akaza H, Carroll P, Cooperberg M R, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol 2012;42:226-236.
11. Akaza H, Hinotsu S, Cooperberg M R, Chung B H, Youl Lee J, Umbas R, et al. Sixth joint meeting of J-CaP and CaPSURE-a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol 2013;43:756-766.
12. Available online: http://demo.nccn.org/professionals/physician_gls/pdf/prostate.pdf
13. Cooperberg M R, Hinotsu S, Namiki M, Ito K, Broering J, Carroll P R, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27:4306-4313.
14. Matthew R. Cooperberg M, Hinotsu S, Namiki M, Carroll P, Akaza H, et al. Trans-pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer. AUA 2013 Annual Meeting (SanDiego) abstract #724.
15. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009;115:3437-3445.
16. Akakura K, Bruchovsky N, Goldenberg S L, Rennie P S, Buckley A R, Sullivan L D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostatespecific antigen. Cancer 1993;71:2782-2790.
17. Crook J M, O'Callaghan C J, Duncan G, Dearnaley D P, Higano C S, Horwitz E M, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903.
18. ASCO Daily News 2012 Annual Meeting Wrap Up. Continuous androgen-deprivation therapy remains standard care for metastatic prostate cancer. SWOG 9346 (INT-1062), (ASCO 2012 abstract #4).
19. Hussain M, Tangen C M, Berry D L, Higano C S, Crawford E D, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-1325.
20. Mitin T, Efstathiou J A, Shipley W U. Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol 2012;9:672-673.
21. Huggins C, Hodges C V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.